Cirrhosis future or investigational therapies: Difference between revisions

Jump to navigation Jump to search
 
(15 intermediate revisions by 4 users not shown)
Line 3: Line 3:
{{CMG}} {{AOEIC}} {{UJ}}
{{CMG}} {{AOEIC}} {{UJ}}
==Overview==
==Overview==
Cirrhosis is a complication of Liver disease which result in irreversible [[scar|scarring]] and loss of [[hepatocytes]]. Although there are many causes but [[Alcohol]] and [[Viral]] [[Hepatitis B]] and [[Hepatitis C|C]] are the main causes of cirrhosis.
Cirrhosis is an irreversible change to the liver, and ongoing research hopes to determine the mechanism of scar formation and how to interrupt or reverse this process.<ref name="pmid12869458">{{cite journal| author=Iredale JP| title=Cirrhosis: new research provides a basis for rational and targeted treatments. | journal=BMJ | year= 2003 | volume= 327 | issue= 7407 | pages= 143-7 | pmid=12869458 | doi=10.1136/bmj.327.7407.143 | pmc=PMC1126509 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12869458  }} </ref> Newer therapies are being developed against [[viral]] causes of liver diseases. New vaccines are currently under development for Hepatitis C, and have already been developed for [[hepatitis B]].
 
Research is going on to determine the mechanism of scar formation and how to interrupt or reverse this process.


==Future or Investigational Therapies==
==Future or Investigational Therapies==
Line 11: Line 9:
*[[Obeticholic acid]] (OCA) for patients with [[primary biliary cirrhosis]].<ref name="pmid21297469">{{cite journal| author=Lindor KD| title=Farnesoid X receptor agonists for primary biliary cirrhosis. | journal=Curr Opin Gastroenterol | year= 2011 | volume= 27 | issue= 3 | pages= 285-8 | pmid=21297469 | doi=10.1097/MOG.0b013e32834452c8 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21297469  }} </ref>
*[[Obeticholic acid]] (OCA) for patients with [[primary biliary cirrhosis]].<ref name="pmid21297469">{{cite journal| author=Lindor KD| title=Farnesoid X receptor agonists for primary biliary cirrhosis. | journal=Curr Opin Gastroenterol | year= 2011 | volume= 27 | issue= 3 | pages= 285-8 | pmid=21297469 | doi=10.1097/MOG.0b013e32834452c8 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21297469  }} </ref>
*Boehringer Ingelheim’s investigational direct-acting antiviral compounds: [[BI 201335]] ([[protease inhibitor]]) plus [[BI 207127]] ([[polymerase inhibitor]]) for the treatment of [[Hepatitis C]] induced Cirrhosis.<ref name="pmid21925126">{{cite journal| author=Zeuzem S, Asselah T, Angus P, Zarski JP, Larrey D, Müllhaupt B et al.| title=Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection. | journal=Gastroenterology | year= 2011 | volume= 141 | issue= 6 | pages= 2047-55; quiz e14 | pmid=21925126 | doi=10.1053/j.gastro.2011.08.051 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21925126  }} </ref>
*Boehringer Ingelheim’s investigational direct-acting antiviral compounds: [[BI 201335]] ([[protease inhibitor]]) plus [[BI 207127]] ([[polymerase inhibitor]]) for the treatment of [[Hepatitis C]] induced Cirrhosis.<ref name="pmid21925126">{{cite journal| author=Zeuzem S, Asselah T, Angus P, Zarski JP, Larrey D, Müllhaupt B et al.| title=Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection. | journal=Gastroenterology | year= 2011 | volume= 141 | issue= 6 | pages= 2047-55; quiz e14 | pmid=21925126 | doi=10.1053/j.gastro.2011.08.051 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21925126  }} </ref>
*[[Entecavir]] in decompensated Hepatitis B Viral cirrhosis.<ref name="pmid20006400">{{cite journal| author=Fontana RJ| title=Entecavir in decompensated HBV cirrhosis: the future is looking brighter. | journal=J Hepatol | year= 2010 | volume= 52 | issue= 2 | pages= 147-9 | pmid=20006400 | doi=10.1016/j.jhep.2009.10.025 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20006400  }} </ref>


==Reference==
==References==
{{reflist|2}}
{{reflist|2}}

Latest revision as of 18:15, 7 September 2012

Cirrhosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cirrhosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Tertiary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case studies

Case #1

Cirrhosis future or investigational therapies On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cirrhosis future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cirrhosis future or investigational therapies

CDC on Cirrhosis future or investigational therapies

Cirrhosis future or investigational therapies in the news

Blogs on Cirrhosis future or investigational therapies

Directions to Hospitals Treating Cirrhosis

Risk calculators and risk factors for Cirrhosis future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-In-Chief: Ujjwal Rastogi, M.B.B.S. [2]

Overview

Cirrhosis is an irreversible change to the liver, and ongoing research hopes to determine the mechanism of scar formation and how to interrupt or reverse this process.[1] Newer therapies are being developed against viral causes of liver diseases. New vaccines are currently under development for Hepatitis C, and have already been developed for hepatitis B.

Future or Investigational Therapies

The following therapies are under trial:

References

  1. Iredale JP (2003). "Cirrhosis: new research provides a basis for rational and targeted treatments". BMJ. 327 (7407): 143–7. doi:10.1136/bmj.327.7407.143. PMC 1126509. PMID 12869458.
  2. Lindor KD (2011). "Farnesoid X receptor agonists for primary biliary cirrhosis". Curr Opin Gastroenterol. 27 (3): 285–8. doi:10.1097/MOG.0b013e32834452c8. PMID 21297469.
  3. Zeuzem S, Asselah T, Angus P, Zarski JP, Larrey D, Müllhaupt B; et al. (2011). "Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection". Gastroenterology. 141 (6): 2047–55, quiz e14. doi:10.1053/j.gastro.2011.08.051. PMID 21925126.
  4. Fontana RJ (2010). "Entecavir in decompensated HBV cirrhosis: the future is looking brighter". J Hepatol. 52 (2): 147–9. doi:10.1016/j.jhep.2009.10.025. PMID 20006400.